Literature DB >> 3783593

Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.

M C Wani, A W Nicholas, M E Wall.   

Abstract

Eight optically active and nine racemic ring A modified analogues of 20(S)-camptothecin were prepared and evaluated for antitumor activity in the L-1210 leukemia system. The ring A mono- and disubstituted analogues displayed a wide variance in activity and potency. It was found that monosubstitution by NH2 or OH at positions 9, 10, or 11 yielded compounds with activity much higher than the parent compound, camptothecin, whereas substitution at position 12 greatly reduced activity. In general, disubstitution in ring A greatly reduced antileukemic activity. Replacement of ring A by heterocyclic rings (thiophene or pyridine) leads to analogues with only moderate activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783593     DOI: 10.1021/jm00161a035

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.

Authors:  S W Carrigan; P C Fox; M E Wall; M C Wani; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

Review 2.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 3.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

4.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

5.  Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

Authors:  T Matsuzaki; T Yokokura; M Mutai; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Physicochemical characterization of 9-aminocamptothecin in aqueous solutions.

Authors:  Shahidur Rahman; Deval Patel; Michalakis Savva
Journal:  AAPS PharmSciTech       Date:  2013-12-03       Impact factor: 3.246

7.  A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.

Authors:  Min Han; Cai-Xia He; Qiu-Li Fang; Xiao-Chun Yang; Yuan-Yuan Diao; Dong-Hang Xu; Qiao-Jun He; Yong-Zhou Hu; Wen-Quan Liang; Bo Yang; Jian-Qing Gao
Journal:  Pharm Res       Date:  2008-12-02       Impact factor: 4.200

8.  Antimetastatic activity of MONCPT in preclinical melanoma mice model.

Authors:  Xiao-Chun Yang; Chong-Xing Tu; Pei-Hua Luo; Hong Zhu; Di-Feng Zhu; Hong-Hai Wu; Xing-Lu Zhou; Wei Lu; Qiao-Jun He; Bo Yang
Journal:  Invest New Drugs       Date:  2009-09-30       Impact factor: 3.850

9.  A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin.

Authors:  Bradley A Hanson; Richard L Schowen; Valentino J Stella
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 10.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.